HC Wainwright assumed coverage on shares of Intec Pharma (NASDAQ:NTEC) in a research note issued to investors on Monday morning, Marketbeat Ratings reports. The firm issued a buy rating on the biotechnology company’s stock.
Several other brokerages have also issued reports on NTEC. Zacks Investment Research lowered Intec Pharma from a buy rating to a hold rating in a research note on Tuesday, January 16th. Oppenheimer set a $15.00 price target on Intec Pharma and gave the company a buy rating in a research note on Monday, December 18th. Maxim Group set a $8.00 price target on Intec Pharma and gave the company a buy rating in a research note on Friday, November 17th. Finally, ValuEngine lowered Intec Pharma from a hold rating to a sell rating in a research note on Thursday, November 16th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company’s stock. Intec Pharma presently has a consensus rating of Buy and an average target price of $11.20.
Shares of Intec Pharma (NTEC) opened at $5.95 on Monday. Intec Pharma has a 1-year low of $4.20 and a 1-year high of $9.80.
COPYRIGHT VIOLATION WARNING: This story was originally posted by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/3229410/hc-wainwright-begins-coverage-on-intec-pharma-ntec.html.
About Intec Pharma
Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.